| TNF signaling pathway |
2.27 |
0.00e+0 |
103/112 (91.96%) |
CXCL1;CXCL5;CXCL10;...
|
| NOD-like receptor signaling pathway |
2.27 |
0.00e+0 |
145/181 (80.11%) |
CXCL8;OAS3;GBP1;...
|
| Measles |
2.15 |
0.00e+0 |
133/139 (95.68%) |
MX1;OAS3;OAS1;...
|
| Legionellosis |
2.09 |
0.00e+0 |
51/57 (89.47%) |
CXCL8;CXCL1;C3;...
|
| Influenza A |
2.05 |
0.00e+0 |
156/172 (90.7%) |
CXCL8;MX1;RSAD2;...
|
| Cytokine-cytokine receptor interaction |
2.05 |
0.00e+0 |
246/295 (83.39%) |
CXCL8;TGFBR2;CXCL1;...
|
| DNA replication |
2.00 |
1.57e-3 |
34/36 (94.44%) |
PCNA;MCM7;FEN1;...
|
| Herpes simplex virus 1 infection |
1.99 |
1.38e-3 |
165/498 (33.13%) |
OAS3;BST2;OAS1;...
|
| IL-17 signaling pathway |
1.96 |
2.44e-3 |
84/94 (89.36%) |
CXCL8;CXCL1;CXCL5;...
|
| Hepatitis B |
1.95 |
2.20e-3 |
151/162 (93.21%) |
PCNA;CXCL8;TGFBR2;...
|
| Cell cycle |
1.95 |
2.00e-3 |
110/124 (88.71%) |
PCNA;CCNB1;CDC20;...
|
| NF-kappa B signaling pathway |
1.95 |
1.83e-3 |
90/104 (86.54%) |
RELB;CXCL8;CXCL1;...
|
| Chagas disease |
1.94 |
3.38e-3 |
93/102 (91.18%) |
CXCL8;TGFBR2;C3;...
|
| Toll-like receptor signaling pathway |
1.94 |
3.14e-3 |
94/104 (90.38%) |
CXCL8;CXCL10;NFKBIA;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.92 |
3.67e-3 |
84/100 (84%) |
CXCL8;CXCL1;CXCL5;...
|
| RIG-I-like receptor signaling pathway |
1.91 |
3.44e-3 |
64/70 (91.43%) |
ISG15;CXCL8;CXCL10;...
|
| Hepatitis C |
1.90 |
3.24e-3 |
139/157 (88.54%) |
IFIT1;MX1;RSAD2;...
|
| Mineral absorption |
1.88 |
3.67e-3 |
48/60 (80%) |
MT1E;ATP1A2;MT1H;...
|
| AGE-RAGE signaling pathway in diabetic complications |
1.88 |
4.05e-3 |
97/100 (97%) |
CXCL8;TGFBR2;F3;...
|
| Cytosolic DNA-sensing pathway |
1.86 |
5.50e-3 |
52/63 (82.54%) |
CXCL10;NFKBIA;DDX58;...
|
| Small cell lung cancer |
1.85 |
6.81e-3 |
90/92 (97.83%) |
NFKBIA;BIRC3;PIK3CD;...
|
| Proteasome |
1.83 |
8.00e-3 |
44/46 (95.65%) |
PSMB9;PSMD11;PSMC2;...
|
| Ribosome biogenesis in eukaryotes |
1.81 |
9.57e-3 |
52/108 (48.15%) |
NOP56;NXT1;DKC1;...
|
| Lipid and atherosclerosis |
1.80 |
1.01e-2 |
190/215 (88.37%) |
CXCL8;CXCL1;NFKBIA;...
|
| TGF-beta signaling pathway |
1.79 |
1.01e-2 |
81/94 (86.17%) |
ID1;TGFBR2;THBS1;...
|
| Osteoclast differentiation |
1.78 |
1.27e-2 |
117/127 (92.13%) |
RELB;TGFBR2;NFKBIA;...
|
| Kaposi sarcoma-associated herpesvirus infection |
1.78 |
1.26e-2 |
172/193 (89.12%) |
CXCL8;CXCL1;C3;...
|
| Epstein-Barr virus infection |
1.77 |
1.53e-2 |
189/202 (93.56%) |
RELB;ISG15;OAS3;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
1.76 |
1.52e-2 |
62/70 (88.57%) |
CXCL8;CXCL1;NFKBIA;...
|
| Rheumatoid arthritis |
1.73 |
1.65e-2 |
78/93 (83.87%) |
CXCL8;CXCL1;CXCL5;...
|
| Other glycan degradation |
-1.72 |
4.71e-2 |
13/18 (72.22%) |
NEU3;HEXA;GLB1;...
|
| Metabolism of xenobiotics by cytochrome P450 |
-1.79 |
2.21e-2 |
49/77 (63.64%) |
CYP2C9;CYP1A1;UGT2B17;...
|
| Glycine, serine and threonine metabolism |
-1.89 |
8.82e-3 |
31/40 (77.5%) |
PSPH;GCAT;AOC3;...
|
| Retinol metabolism |
-1.89 |
1.32e-2 |
41/68 (60.29%) |
CYP2C9;CYP1A1;RDH16;...
|
| Oxidative phosphorylation |
-1.98 |
1.76e-2 |
93/133 (69.92%) |
ATP6V1A;ATP6V0A1;ATP5F1A;...
|
